Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic

​Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 20.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s) for this live continuing medical education activity must complete the CME Request for Credit Survey by Thursday, February 22. (The link will be posted below prior to the conference.) Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.


Statement of Educational Need, Target Audience, and Learning Objectives
Lung cancer is the leading cause of cancer-related death in the United States and globally. In 2017, the estimated number of deaths from lung cancer in the United States (155,870) and worldwide (over 1.6 million people) is staggering.

Within the last 15 years, research has provided insights into the molecular nuances that stratify different types of non-small-cell lung cancer (NSCLC). In the past, an approach to target all NSCLC with cytotoxic chemotherapeutic agents, a "one size fits all" approach, provided a small measurable benefit but often with response rates of less than 20%. Current research aims for personalized treatment options by characterizing the primary and specific genetic alterations in an individual patient's tumor. Identifying therapeutic targets, verifying these targets, developing and testing therapeutics for optimal treatment, and evaluating mechanisms of resistance should treatment fail are processes requiring a multi-disciplinary approach and collaborative efforts.

Two of the most common genetic alterations can be used to illustrate the growth in genomics/precision medicine in lung cancer. Logically, patients with an EGFR mutation have a better response rate to EGFR tyrosine kinase inhibitors, such as gefitinib or erlotinib, than those without the EGFR mutation. NSCLC patients with EML4/ALK fusions respond to a different drug (crizotinib). Additionally, it is rare for ALK fusions and EGFR mutations to occur concurrently. To date, the molecular origins of lung cancer can stem from mutations in many other genes such as KRAS, NRAS, BRAF, HER2, MEK1, AKT1, PIK3CA, as well as from ROS fusions or PDGFR amplification. It was reported by The Lung Cancer Mutation Consortium that more than 60% of lung adenocarcinomas harbor one of the above-listed molecular drivers. Thus, a precise approach to target a patient's tumor type is optimal and beneficial, and truly requires the collaboration of many. This involves discussion of physicians with their basic, translational, and clinical lung cancer research colleagues, a necessary forum that this conference will provide.

Since the 2016 conference, phase III trials in immunotherapy have resulted in the March 2015 approval of nivolumab for the treatment of certain metastatic NSCLC (particularly of squamous cell-type) that have progress despite chemotherapy. Pembrolizumab and atezolizumab both have gained FDA Breakthrough Therapy designation for non-small-cell lung cancer in October 2014 and February 2015, respectively. Major strides in harnessing the immune system to treat lung cancer have been made in the short time since the last two conference in this series convened. Notably, since the last conference (between August 1, 2016, and July 31, 2017), three new therapies have been approved or approved for new use in lung cancer by the FDA (brigatinib, dabrafenib/trametinib, and atezolizumab). The ability to discuss the data and power progress forward on this new treatment front and emerging resistance to other treatment options will be possible in our conference forum.

Early detection remains critical in improving the survival rates in those diagnosed with cancer. The five-year survival rate for early-diagnosed lung cancers (55%) is significantly higher than those diagnosed at later stages (5%). Technologies in early detection, such as continued recommendations for screening and, most recently, the potential of liquid biopsies and identifying circulating tumor DNA, also provide opportunities for collaboration of physicians and translational/basic research colleagues.

Bridging the gap between what physicians understand about cancer biology and its application to clinical oncology is critical to the implementation of the most current approved molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer.  Moreover, facilitating the interface between physicians and scientists will increase physicians' knowledge of the epidemiological implications of lung cancer incidence and the contributions of laboratory research to drug development and alternate strategies should a cancer become resistant to therapy.

After participating in this CME activity, physicians should be able to:

  1. Demonstrate a knowledge of the early steps in lung oncogenesis and opportunities in early detection of the disease through screening and liquid biopsies.
  2. Analyze the state of both targeted therapy and immunotherapy research and treatment in lung cancer, including biomarkers and resistance.
  3. Articulate current topics in both genetics and resistance through discussion of heterogeneity and evolution.
  4. Assess the current state of research and treatment in small-cell lung cancer.
  5. Evaluate how the tumor microenvironment in lung cancer is involved in current research and treatment.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support
This activity is supported by grants and will be disclosed at the activity.  

Questions about CME?
Please contact the Office of CME at (215) 440-9300 or